1.31
1.55%
0.02
Dopo l'orario di chiusura:
1.27
-0.04
-3.05%
Ocuphire Pharma Inc Borsa (OCUP) Ultime notizie
Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com UK
Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan
OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
OFS Credit to offer preferred stock in public offering - MSN
Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada
Is OCGN’s price to cash per share ratio a concern for investors? - US Post News
Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World
Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance
All the Doctor Odyssey guest stars we know so far - Hidden Remote
Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR
Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News
American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com India
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - Yahoo Finance UK
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial - GlobeNewswire
Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - StockTitan
Ocuphire Pharma Inc [OCUP] Chief Scientific & Dev. Ofc. makes an insider purchase of 3,500 shares worth 6178.0. - Knox Daily
OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com
OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com India
OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada
Analysts review Ocuphire Pharma Inc’s rating - Knox Daily
There is no way Ocuphire Pharma Inc (OCUP) can keep these numbers up - SETE News
Ocuphire Pharma Inc (OCUP) stock: A year of ups and downs - US Post News
Ocuphire Pharma (NASDAQ:OCUP) Stock Quotes, Forecast and News Summary - Benzinga
Ocuphire Pharma Inc’s latest rating changes from various analysts - Knox Daily
Vanguard Group Inc. Purchases 64,400 Shares of Ocuphire Pharma, Inc. (NASDAQ:OCUP) - Defense World
Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher - Simply Wall St
Ocuphire Pharma Announces 2024 Second Quarter Financial Results - Vision Monday
Ocuphire Pharma (STU:R3X1) EPS (Basic) : €-0.50 (TTM As of Jun. 2024) - GuruFocus.com
Ocuphire Pharma (STU:R3X1) EV-to-Revenue : -0.39 (As of Aug. 18, 2024) - GuruFocus.com
OCUP (Ocuphire Pharma) 3-Year FCF Growth Rate : 67.10% (As of Jun. 2024) - GuruFocus.com
OCUP (Ocuphire Pharma) Debt-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
OCUP (Ocuphire Pharma) 50-Day SMA : $1.71 (As of Aug. 17, 2024) - GuruFocus.com
OCUP (Ocuphire Pharma) Net Income : $-14.11 Mil (TTM As of Jun. 2024) - GuruFocus.com
Canaccord Genuity Group Reaffirms Buy Rating for Ocuphire Pharma (NASDAQ:OCUP) - Defense World
Ocuphire Pharma (FRA:R3X1) PE Ratio (TTM) : At Loss (As of Aug. 18, 2024) - GuruFocus.com
Was anything negative for Ocuphire Pharma Inc (OCUP) stock last session? - US Post News
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasted to Post Q3 2024 Earnings of ($0.30) Per Share - Defense World
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Ocuphire shares price target cut, buy rating held on FDA approval milestone - Investing.com Canada
Ocuphire Pharma Inc (OCUP) Stock: A Year of Declines and Increases - The InvestChronicle
Ocuphire shares price target cut, buy rating held on FDA approval milestone - Investing.com
Financial Health Check: Examining Ocuphire Pharma Inc (OCUP)’s Key Ratios - The Dwinnex
OCUP stock touches 52-week low at $1.47 amid market challenges - Investing.com
OCUP stock touches 52-week low at $1.47 amid market challenges - Investing.com Canada
OCUP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update - GlobeNewswire
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance UK
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update - StockTitan
Virtu Financial LLC Takes $36,000 Position in Ocuphire Pharma, Inc. (NASDAQ:OCUP) - Defense World
Ocuphire Pharma to Present at Two Investor Conferences in August - GlobeNewswire
Ocuphire Pharma to Present at Two Investor Conferences in August - StockTitan
Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):